TY - JOUR
T1 - The Deep Dementia Phenotyping (DEMON) Network
T2 - A global platform for innovation using data science and artificial intelligence
AU - Ranson, Janice M.
AU - Khleifat, Ahmad Al
AU - Lyall, Donald M.
AU - Newby, Danielle
AU - Winchester, Laura M.
AU - Proitsi, Petroula
AU - Veldsman, Michele
AU - Rittman, Timothy
AU - Marzi, Sarah
AU - Yao, Zhi
AU - Skene, Nathan
AU - Bettencourt, Conceição
AU - Kormilitzin, Andrey
AU - Foote, Isabelle F.
AU - Golborne, Cecilia
AU - Lourida, Ilianna
AU - Bucholc, Magda
AU - Tang, Eugene
AU - Oxtoby, Neil P.
AU - Bagshaw, Peter
AU - Walker, Zuzana
AU - Everson, Richard
AU - Ballard, Clive G.
AU - van Duijn, Cornelia M.
AU - Langa, Kenneth M.
AU - MacLeod, Malcolm
AU - Rockwood, Kenneth
AU - Llewellyn, David J.
N1 - Publisher Copyright:
© 2022 the Alzheimer's Association.
PY - 2022/12
Y1 - 2022/12
N2 - Background: The increasing availability of large high-dimensional data from experimental medicine, population-based and clinical cohorts, clinical trials, and electronic health records has the potential to transform dementia research. Our ability to make best use of this rich data will depend on utilisation of advanced machine learning and artificial intelligence (AI) techniques and collaboration across disciplinary and geographic boundaries. Method: The Deep Dementia Phenotyping (DEMON) Network launched in 20191 to support the growing interest in machine learning and AI. Led by Director Prof David Llewellyn and Deputy Director Dr Janice Ranson, the leadership team additionally includes 5 Theme Leads and 14 Working Group Leads, supported by an international Steering Committee of world-leading academics. Core funding is provided by Alzheimer’s Research UK, the Alan Turing Institute and the University of Exeter, with additional support from strategic partners including the UK Dementia Research Institute and the Alzheimer’s Society. Grand Challenges were established at a National Strategy Workshop in June 2020. Multidisciplinary Working Groups were formed to coordinate practical activities in seven key areas: Genetics and omics, experimental medicine, drug discovery and trials optimisation, biomarkers, imaging, dementia prevention, and applied models and digital health. Additional Special Interest Groups coordinate topic specific collaborations. Result: Membership on 4th February 2022 comprised 1,321 individuals from 61 countries across 6 continents (see Figure). Areas of expertise include dementia research (904; 68%), data science (692; 52%), clinical practice (244; 18%), industry (162; 12%), and regulation (26; 2%). Individual membership is free, and regular knowledge transfer events are provided including a monthly seminar series, talks and workshops, training, networking, and early career development. Each Working Group meets monthly, with multiple grants, reviews, and original research articles in progress. Eight state of the science position papers are in preparation, resulting from a Symposium held in April 2021. In January 2022, 110 early career researchers participated in the Network’s flagship event ‘NEUROHACK’, a 4-day competitive global hackathon, with pilot grants awarded to those generating the most innovative solutions. Conclusion: The DEMON Network is a rapidly growing global platform for innovation that is supporting the global dementia research community to collaborate. Find out more at demondementia.com.
AB - Background: The increasing availability of large high-dimensional data from experimental medicine, population-based and clinical cohorts, clinical trials, and electronic health records has the potential to transform dementia research. Our ability to make best use of this rich data will depend on utilisation of advanced machine learning and artificial intelligence (AI) techniques and collaboration across disciplinary and geographic boundaries. Method: The Deep Dementia Phenotyping (DEMON) Network launched in 20191 to support the growing interest in machine learning and AI. Led by Director Prof David Llewellyn and Deputy Director Dr Janice Ranson, the leadership team additionally includes 5 Theme Leads and 14 Working Group Leads, supported by an international Steering Committee of world-leading academics. Core funding is provided by Alzheimer’s Research UK, the Alan Turing Institute and the University of Exeter, with additional support from strategic partners including the UK Dementia Research Institute and the Alzheimer’s Society. Grand Challenges were established at a National Strategy Workshop in June 2020. Multidisciplinary Working Groups were formed to coordinate practical activities in seven key areas: Genetics and omics, experimental medicine, drug discovery and trials optimisation, biomarkers, imaging, dementia prevention, and applied models and digital health. Additional Special Interest Groups coordinate topic specific collaborations. Result: Membership on 4th February 2022 comprised 1,321 individuals from 61 countries across 6 continents (see Figure). Areas of expertise include dementia research (904; 68%), data science (692; 52%), clinical practice (244; 18%), industry (162; 12%), and regulation (26; 2%). Individual membership is free, and regular knowledge transfer events are provided including a monthly seminar series, talks and workshops, training, networking, and early career development. Each Working Group meets monthly, with multiple grants, reviews, and original research articles in progress. Eight state of the science position papers are in preparation, resulting from a Symposium held in April 2021. In January 2022, 110 early career researchers participated in the Network’s flagship event ‘NEUROHACK’, a 4-day competitive global hackathon, with pilot grants awarded to those generating the most innovative solutions. Conclusion: The DEMON Network is a rapidly growing global platform for innovation that is supporting the global dementia research community to collaborate. Find out more at demondementia.com.
UR - http://www.scopus.com/inward/record.url?scp=85144305942&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85144305942&partnerID=8YFLogxK
U2 - 10.1002/alz.067308
DO - 10.1002/alz.067308
M3 - Article
C2 - 36537478
AN - SCOPUS:85144305942
SN - 1552-5260
VL - 18
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - S2
M1 - e067308
ER -
